<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0008438.ref085">
 <label>85</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Devine</surname>
   <given-names>DV</given-names>
  </name>, 
  <name>
   <surname>Schubert</surname>
   <given-names>P</given-names>
  </name>. 
  <article-title>Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk</article-title>. 
  <source>Hematology/Oncology Clinics</source>. 
  <year>2016</year>;
  <volume>30</volume>(
  <issue>3</issue>):
  <fpage>609</fpage>â€“
  <lpage>17</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.hoc.2016.01.005</pub-id>
  <?supplied-pmid 27112999?>
  <pub-id pub-id-type="pmid">27112999</pub-id>
 </mixed-citation>
</ref>
